Inhibition of COX-2 in colon cancer modulates tumor growth and MDR-1 expression to enhance tumor regression in therapy-refractory cancers in vivo

Mahbuba Rahman, Krithika Selvarajan, Mohammad R. Hasan, Annie P. Chan, Chaoyang Jin, Jieun Kim, Simon K. Chan, Nhu D. Le, Young Bae Kim, Isabella T. Tai

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Higher cyclooxygenase 2 (COX-2) expression is often observed in aggressive colorectal cancers (CRCs). Here, we attempt to examine the association between COX-2 expression in therapy-refractory CRC, how it affects chemosensitivity, and whether, in primary tumors, it is predictive of clinical outcomes. Our results revealed higher COX-2 expression in chemoresistant CRC cells and tumor xenografts. In vitro, the combination of either aspirin or celecoxib with 5-fluorouracil (5-FU) was capable of improving chemosensitivity in chemorefractory CRC cells, but a synergistic effect with 5-FU could only be demonstrated with celecoxib. To examine the potential clinical significance of these observations, in vivo studies were undertaken, which also showed that the greatest tumor regression was achieved in chemoresistant xenografts after chemotherapy in combination with celecoxib, but not aspirin. We also noted that these chemoresistant tumors with higher COX-2 expression had a more aggressive growth rate. Given the dramatic response to a combination of celecoxib + 5-FU, the possibility that celecoxib may modulate chemosensitivity as a result of its ability to inhibit MDR-1 was examined. In addition, assessment of a tissue microarray consisting of 130 cases of CRCs revealed that, in humans, higher COX-2 expression was associated with poorer survival with a 68% increased risk of mortality, indicating that COX-2 expression is a marker of poor clinical outcome. The findings of this study point to a potential benefit of combining COX-2 inhibitors with current regimens to achieve better response in the treatment of therapy-refractory CRC and in using COX-2 expression as a prognostic marker to help identify individuals who would benefit the greatest from closer follow-up and more aggressive therapy.

Original languageEnglish
Pages (from-to)624-633
Number of pages10
JournalNeoplasia (United States)
Volume14
Issue number7
DOIs
Publication statusPublished - Jul 2012
Externally publishedYes

Fingerprint

Celecoxib
Cyclooxygenase 2
Colonic Neoplasms
Colorectal Neoplasms
Growth
Neoplasms
Fluorouracil
Heterografts
Therapeutics
Aspirin
Cyclooxygenase 2 Inhibitors
Combination Drug Therapy
Biomarkers
Survival
Mortality

ASJC Scopus subject areas

  • Cancer Research

Cite this

Inhibition of COX-2 in colon cancer modulates tumor growth and MDR-1 expression to enhance tumor regression in therapy-refractory cancers in vivo. / Rahman, Mahbuba; Selvarajan, Krithika; Hasan, Mohammad R.; Chan, Annie P.; Jin, Chaoyang; Kim, Jieun; Chan, Simon K.; Le, Nhu D.; Kim, Young Bae; Tai, Isabella T.

In: Neoplasia (United States), Vol. 14, No. 7, 07.2012, p. 624-633.

Research output: Contribution to journalArticle

Rahman, Mahbuba ; Selvarajan, Krithika ; Hasan, Mohammad R. ; Chan, Annie P. ; Jin, Chaoyang ; Kim, Jieun ; Chan, Simon K. ; Le, Nhu D. ; Kim, Young Bae ; Tai, Isabella T. / Inhibition of COX-2 in colon cancer modulates tumor growth and MDR-1 expression to enhance tumor regression in therapy-refractory cancers in vivo. In: Neoplasia (United States). 2012 ; Vol. 14, No. 7. pp. 624-633.
@article{f86c4788f7364615bd20a3e2ea6ec865,
title = "Inhibition of COX-2 in colon cancer modulates tumor growth and MDR-1 expression to enhance tumor regression in therapy-refractory cancers in vivo",
abstract = "Higher cyclooxygenase 2 (COX-2) expression is often observed in aggressive colorectal cancers (CRCs). Here, we attempt to examine the association between COX-2 expression in therapy-refractory CRC, how it affects chemosensitivity, and whether, in primary tumors, it is predictive of clinical outcomes. Our results revealed higher COX-2 expression in chemoresistant CRC cells and tumor xenografts. In vitro, the combination of either aspirin or celecoxib with 5-fluorouracil (5-FU) was capable of improving chemosensitivity in chemorefractory CRC cells, but a synergistic effect with 5-FU could only be demonstrated with celecoxib. To examine the potential clinical significance of these observations, in vivo studies were undertaken, which also showed that the greatest tumor regression was achieved in chemoresistant xenografts after chemotherapy in combination with celecoxib, but not aspirin. We also noted that these chemoresistant tumors with higher COX-2 expression had a more aggressive growth rate. Given the dramatic response to a combination of celecoxib + 5-FU, the possibility that celecoxib may modulate chemosensitivity as a result of its ability to inhibit MDR-1 was examined. In addition, assessment of a tissue microarray consisting of 130 cases of CRCs revealed that, in humans, higher COX-2 expression was associated with poorer survival with a 68{\%} increased risk of mortality, indicating that COX-2 expression is a marker of poor clinical outcome. The findings of this study point to a potential benefit of combining COX-2 inhibitors with current regimens to achieve better response in the treatment of therapy-refractory CRC and in using COX-2 expression as a prognostic marker to help identify individuals who would benefit the greatest from closer follow-up and more aggressive therapy.",
author = "Mahbuba Rahman and Krithika Selvarajan and Hasan, {Mohammad R.} and Chan, {Annie P.} and Chaoyang Jin and Jieun Kim and Chan, {Simon K.} and Le, {Nhu D.} and Kim, {Young Bae} and Tai, {Isabella T.}",
year = "2012",
month = "7",
doi = "10.1593/neo.12486",
language = "English",
volume = "14",
pages = "624--633",
journal = "Neoplasia",
issn = "1522-8002",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Inhibition of COX-2 in colon cancer modulates tumor growth and MDR-1 expression to enhance tumor regression in therapy-refractory cancers in vivo

AU - Rahman, Mahbuba

AU - Selvarajan, Krithika

AU - Hasan, Mohammad R.

AU - Chan, Annie P.

AU - Jin, Chaoyang

AU - Kim, Jieun

AU - Chan, Simon K.

AU - Le, Nhu D.

AU - Kim, Young Bae

AU - Tai, Isabella T.

PY - 2012/7

Y1 - 2012/7

N2 - Higher cyclooxygenase 2 (COX-2) expression is often observed in aggressive colorectal cancers (CRCs). Here, we attempt to examine the association between COX-2 expression in therapy-refractory CRC, how it affects chemosensitivity, and whether, in primary tumors, it is predictive of clinical outcomes. Our results revealed higher COX-2 expression in chemoresistant CRC cells and tumor xenografts. In vitro, the combination of either aspirin or celecoxib with 5-fluorouracil (5-FU) was capable of improving chemosensitivity in chemorefractory CRC cells, but a synergistic effect with 5-FU could only be demonstrated with celecoxib. To examine the potential clinical significance of these observations, in vivo studies were undertaken, which also showed that the greatest tumor regression was achieved in chemoresistant xenografts after chemotherapy in combination with celecoxib, but not aspirin. We also noted that these chemoresistant tumors with higher COX-2 expression had a more aggressive growth rate. Given the dramatic response to a combination of celecoxib + 5-FU, the possibility that celecoxib may modulate chemosensitivity as a result of its ability to inhibit MDR-1 was examined. In addition, assessment of a tissue microarray consisting of 130 cases of CRCs revealed that, in humans, higher COX-2 expression was associated with poorer survival with a 68% increased risk of mortality, indicating that COX-2 expression is a marker of poor clinical outcome. The findings of this study point to a potential benefit of combining COX-2 inhibitors with current regimens to achieve better response in the treatment of therapy-refractory CRC and in using COX-2 expression as a prognostic marker to help identify individuals who would benefit the greatest from closer follow-up and more aggressive therapy.

AB - Higher cyclooxygenase 2 (COX-2) expression is often observed in aggressive colorectal cancers (CRCs). Here, we attempt to examine the association between COX-2 expression in therapy-refractory CRC, how it affects chemosensitivity, and whether, in primary tumors, it is predictive of clinical outcomes. Our results revealed higher COX-2 expression in chemoresistant CRC cells and tumor xenografts. In vitro, the combination of either aspirin or celecoxib with 5-fluorouracil (5-FU) was capable of improving chemosensitivity in chemorefractory CRC cells, but a synergistic effect with 5-FU could only be demonstrated with celecoxib. To examine the potential clinical significance of these observations, in vivo studies were undertaken, which also showed that the greatest tumor regression was achieved in chemoresistant xenografts after chemotherapy in combination with celecoxib, but not aspirin. We also noted that these chemoresistant tumors with higher COX-2 expression had a more aggressive growth rate. Given the dramatic response to a combination of celecoxib + 5-FU, the possibility that celecoxib may modulate chemosensitivity as a result of its ability to inhibit MDR-1 was examined. In addition, assessment of a tissue microarray consisting of 130 cases of CRCs revealed that, in humans, higher COX-2 expression was associated with poorer survival with a 68% increased risk of mortality, indicating that COX-2 expression is a marker of poor clinical outcome. The findings of this study point to a potential benefit of combining COX-2 inhibitors with current regimens to achieve better response in the treatment of therapy-refractory CRC and in using COX-2 expression as a prognostic marker to help identify individuals who would benefit the greatest from closer follow-up and more aggressive therapy.

UR - http://www.scopus.com/inward/record.url?scp=84865629141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865629141&partnerID=8YFLogxK

U2 - 10.1593/neo.12486

DO - 10.1593/neo.12486

M3 - Article

VL - 14

SP - 624

EP - 633

JO - Neoplasia

JF - Neoplasia

SN - 1522-8002

IS - 7

ER -